Even before my grandfather’s passing, I was familiar with death. Medicine had made it so. For two years as a medical student, most of my days were spent on the wards, contributing to morning rounds, running clinical tasks and guiding discussions with families. Some days, we delivered and celebrated babies. On others, we had hard conversations. “I’m sorry,” I would say. “I wish things were different.” It didn’t take me long to recognize how easily a beginning could give way to an ending.
Is this you? As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work.
Claim your profile
Articles by Alisha M. Yi
#VisualAbstract: Switching from ticagrelor to clopidogrel may demonstrate benefit in patients with large body mass index and prior myocardial infarction | 2 Minute Medicine
1. A deescalation strategy involving switching from ticagrelor to clopidogrel in patients with acute myocardial infarction (AMI) was associated with improved clinical outcomes in those with lower body mass index (BMI) but not those with higher BMI. Evidence Rating Level: 1 (Excellent) Study Rundown: The current standard of care for individuals with AMI involves percutaneous coronary intervention (PCI) followed by antiplatelet therapy.
VisualAbstract: Ultrasound-guided rendezvous and precut sphincterotomy similarly effective as salvage techniques for biliary obstruction
1. In patients with difficult biliary cannulation in the setting of benign disease, endoscopic ultrasound-guided rendezvous and precut sphincterotomy had similar technical success rates. 2. Both techniques exhibited similar procedure times and rate of adverse events, although radiation exposure was significantly higher in patients who underwent ultrasound-guided rendezvous.
VisualAbstract: Ultrasound-guided rendezvous and precut sphincterotomy similarly effective as salvage techniques for biliary obstruction
1. In patients with difficult biliary cannulation in the setting of benign disease, endoscopic ultrasound-guided rendezvous and precut sphincterotomy had similar technical success rates. 2. Both techniques exhibited similar procedure times and rate of adverse events, although radiation exposure was significantly higher in patients who underwent ultrasound-guided rendezvous.
#VisualAbstract: Long-term Colchicine Does Not Reduce Recurrent Events Following Ischemic Stroke
1. Incidence of recurrent ischemic stroke, myocardial infarction, cardiac arrest, and hospitalization was not statistically significant between both groups. 2. Patients receiving colchicine had lower CRP levels than those assigned to usual care. Evidence Rating Level: 1 (Excellent) Study Rundown: Anti-inflammatory therapy with long-term colchicine has been shown to prevent vascular recurrence in coronary artery disease.
#VisualAbstract: Immunotherapy-Based Total Neoadjuvant Therapy for Locally Advanced Rectal Cancer
1. The complete response rates (pathological and clinical) were similar (~55%) in both groups. 2. Grade 3-4 adverse events rates were similar (~43%) in both groups with thrombocytopenia and neutropenia being the most common. Evidence Rating Level: 2 (Good) Study Rundown: Total neoadjuvant therapy (TNT) for locally advanced rectal cancer showed superiority compared to traditional approaches, however still have a low pathological complete response rate.
#VisualAbstract: Immunotherapy-Based Total Neoadjuvant Therapy for Locally Advanced Rectal Cancer
1. The complete response rates (pathological and clinical) were similar (~55%) in both groups. 2. Grade 3-4 adverse events rates were similar (~43%) in both groups with thrombocytopenia and neutropenia being the most common. Evidence Rating Level: 2 (Good) Study Rundown: Total neoadjuvant therapy (TNT) for locally advanced rectal cancer showed superiority compared to traditional approaches, however still have a low pathological complete response rate.
#VisualAbstract: Pazopanib does not improve disease-free survival post-metastasectomy for renal cell carcinoma patients
1. Pazopanib did not improve disease-free survival in post-metastasectomy renal cell carcinoma patients 2. There was a concerning trend favouring placebo when assessing overall survival, suggesting a negative impact of pazopanib. Evidence Rating Level: 1(Excellent) Study Rundown: The E2810 trial was a randomized, double-blind phase III trial assessing the impact of pazopanib on patients with metastatic renal cell carcinoma (mRCC) who are post-metastasectomy.
#VisualAbstract: Pazopanib does not improve disease-free survival post-metastasectomy for renal cell carcinoma patients
1. Pazopanib did not improve disease-free survival in post-metastasectomy renal cell carcinoma patients 2. There was a concerning trend favouring placebo when assessing overall survival, suggesting a negative impact of pazopanib. Evidence Rating Level: 1(Excellent) Study Rundown: The E2810 trial was a randomized, double-blind phase III trial assessing the impact of pazopanib on patients with metastatic renal cell carcinoma (mRCC) who are post-metastasectomy.
#VisualAbstract: Iptacopan improves hematologic and clinical outcomes in paroxysmal nocturnal hemoglobinuria
1. In two clinical trials, iptacopan in patients with paroxysmal nocturnal hemoglobinuria (PNH) improved hemoglobin levels compared to anti-C5-treated patients and those without complement inhibitors. 2. Patients who received iptacopan generally exhibited improved secondary outcomes, including less fatigue, reduced reticulocyte and bilirubin levels, and decreased breakthrough hemolysis.
#VisualAbstract: Iptacopan improves hematologic and clinical outcomes in paroxysmal nocturnal hemoglobinuria
1. In two clinical trials, iptacopan in patients with paroxysmal nocturnal hemoglobinuria (PNH) improved hemoglobin levels compared to anti-C5-treated patients and those without complement inhibitors. 2. Patients who received iptacopan generally exhibited improved secondary outcomes, including less fatigue, reduced reticulocyte and bilirubin levels, and decreased breakthrough hemolysis.
#VisualAbstract: Preoperative breast MRI may reduce need for adjuvant radiotherapy for women with unifocal breast cancer
1. There were similar rates of ipsilateral invasive recurrence among the postoperative adjuvant radiotherapy group (group 1) and non-radiotherapy group (group 2). 2. 2% of patients in the total cohort underwent mastectomy and all of them were in the non-radiotherapy group. Evidence Rating Level: 1 (Excellent) Study Rundown: Adjuvant breast radiotherapy is a common practice in early breast cancer treatment, although some suggests it may be overtreatment.
#VisualAbstract: Preoperative breast MRI may reduce need for adjuvant radiotherapy for women with unifocal breast cancer
1. There were similar rates of ipsilateral invasive recurrence among the postoperative adjuvant radiotherapy group (group 1) and non-radiotherapy group (group 2). 2. 2% of patients in the total cohort underwent mastectomy and all of them were in the non-radiotherapy group. Evidence Rating Level: 1 (Excellent) Study Rundown: Adjuvant breast radiotherapy is a common practice in early breast cancer treatment, although some suggests it may be overtreatment.
#VisualAbstract: Cervical intraepithelial neoplasia grade 2 and risk of preterm birth
1. For women with cervical intraepithelial neoplasia grade 2 (CIN2), the risk of preterm birth was similar for those who underwent active surveillance compared to immediate loop electrosurgical excision procedure (LEEP) 2. The risk of preterm birth was greater for those who underwent delayed LEEP compared to immediate LEEP. Evidence Rating Level: 2 (Good) Cervical intraepithelial neoplasia grade 2 (CIN2) is typically managed via surgical excision.
#VisualAbstract: Cervical intraepithelial neoplasia grade 2 and risk of preterm birth
1. For women with cervical intraepithelial neoplasia grade 2 (CIN2), the risk of preterm birth was similar for those who underwent active surveillance compared to immediate loop electrosurgical excision procedure (LEEP) 2. The risk of preterm birth was greater for those who underwent delayed LEEP compared to immediate LEEP. Evidence Rating Level: 2 (Good) Cervical intraepithelial neoplasia grade 2 (CIN2) is typically managed via surgical excision.
#VisualAbstract: Palliative care services are underutilized at end of life in Ontario, Canada
1. In Ontario Canada, only 50% of home care clients received at least 1 or more palliative home care visits during their last 6 months of life. 2. The Risk Evaluation for Support: Predictions for Elder-life in their Communities Tool (RESPECT) served as a valuable prognostic model to provide early identification of palliative care needs.
#VisualAbstract: Palliative care services are underutilized at end of life in Ontario, Canada
1. In Ontario Canada, only 50% of home care clients received at least 1 or more palliative home care visits during their last 6 months of life. 2. The Risk Evaluation for Support: Predictions for Elder-life in their Communities Tool (RESPECT) served as a valuable prognostic model to provide early identification of palliative care needs.
#VisualAbstract: Atezolizumab in addition to bevacizumab and platinum-based chemotherapy improves survival in metastatic cervical cancer
1. The Atezolizumab group demonstrated significantly greater progression-free and overall survival among patients with metastatic, persistent, or recurrent cervical cancer. 2. Grade 3 or worse adverse events were comparable in both groups. Evidence Rating Level: 1 (Excellent) Study Rundown: A previous large-scale trial has shown improved overall survival among patients with cervical cancer treated with bevacizumab and chemotherapy.
#VisualAbstract: Atezolizumab in addition to bevacizumab and platinum-based chemotherapy improves survival in metastatic cervical cancer
1. The Atezolizumab group demonstrated significantly greater progression-free and overall survival among patients with metastatic, persistent, or recurrent cervical cancer. 2. Grade 3 or worse adverse events were comparable in both groups. Evidence Rating Level: 1 (Excellent) Study Rundown: A previous large-scale trial has shown improved overall survival among patients with cervical cancer treated with bevacizumab and chemotherapy.
#VisualAbstract: Ubrogepant is safe and effective for acute treatment of migraine prodrome
1. Absence of moderate or severe headache 24 hours following administration of treatment drug was significantly greater among patients with migraine attacks that were treated with ubrogepant during the prodrome phase. 2. Adverse events were slightly more frequent in the ubrogepant group versus placebo. Evidence Rating Level: 1 (Excellent) Study Rundown: Ubrogepant, a calcitonin gene-related peptide (cGRP) receptor antagonist, is approved for acute migraine treatment.
#VisualAbstract: Ubrogepant is safe and effective for acute treatment of migraine prodrome
By signing up for our newsletter, you agree to our Terms of Use and Privacy Policy
#VisualAbstract: Ubrogepant is safe and effective for acute treatment of migraine prodrome
1. Absence of moderate or severe headache 24 hours following administration of treatment drug was significantly greater among patients with migraine attacks that were treated with ubrogepant during the prodrome phase. 2. Adverse events were slightly more frequent in the ubrogepant group versus placebo. Evidence Rating Level: 1 (Excellent) Study Rundown: Ubrogepant, a calcitonin gene-related peptide (cGRP) receptor antagonist, is approved for acute migraine treatment.
#VisualAbstract: Pembrolizumab and chemotherapy combination improves survival in advanced pleural mesothelioma
1. Patients in the pembrolizumab plus chemotherapy group reported a significantly greater overall survival compared to those in the chemotherapy alone group (17.3 months vs. 16.1 months). 2. Grade 5 adverse events were comparable in both groups. Evidence Rating Level: 1 (Excellent) Study Rundown: Pleural mesothelioma often presents at an advanced stage, and platinum–pemetrexed chemotherapy is a standard treatment.
#VisualAbstract: Pembrolizumab and chemotherapy combination improves survival in advanced pleural mesothelioma
1. Patients in the pembrolizumab plus chemotherapy group reported a significantly greater overall survival compared to those in the chemotherapy alone group (17.3 months vs. 16.1 months). 2. Grade 5 adverse events were comparable in both groups. Evidence Rating Level: 1 (Excellent) Study Rundown: Pleural mesothelioma often presents at an advanced stage, and platinum–pemetrexed chemotherapy is a standard treatment.
#VisualAbstract: Curcumin-piperine supplementation may lead to lower inflammation in post-stroke patients
1. Supplementation with curcumin-piperine resulted in significantly reduced serum levels of inflammatory markers, total cholesterol, triglycerides, weight, waist circumference, and systolic and diastolic blood pressure in post-stroke patients. 2. Curcumin-piperine supplementation did not lead to changes in quality-of-life indicators in post-stroke patients.
#VisualAbstract: Curcumin-piperine supplementation may lead to lower inflammation in post-stroke patients
1. Supplementation with curcumin-piperine resulted in significantly reduced serum levels of inflammatory markers, total cholesterol, triglycerides, weight, waist circumference, and systolic and diastolic blood pressure in post-stroke patients. 2. Curcumin-piperine supplementation did not lead to changes in quality-of-life indicators in post-stroke patients.
#VisualAbstract: Pembrolizumab enhances progression-free survival in patients with HER2-positive gastro-esophageal cancer
1. Progression-free survival was significantly greater among patients in the pembrolizumab group compared to placebo (10.0 vs. 8.1 months). 2. 1% of patients in each group experienced treatment-related mortality. Evidence Rating Level: 1 (Excellent) Study Rundown: Limited evidence exists on combined PD-1 and HER2 blockade with chemotherapy in HER2-positive gastro-esophageal cancer.
#VisualAbstract: Pembrolizumab enhances progression-free survival in patients with HER2-positive gastro-esophageal cancer
1. Progression-free survival was significantly greater among patients in the pembrolizumab group compared to placebo (10.0 vs. 8.1 months). 2. 1% of patients in each group experienced treatment-related mortality. Evidence Rating Level: 1 (Excellent) Study Rundown: Limited evidence exists on combined PD-1 and HER2 blockade with chemotherapy in HER2-positive gastro-esophageal cancer.
#VisualAbstract: Delayed cord clamping reduces mortality in infants born pre-term
1. Deferred (delayed) cord clamping significantly reduced mortality before discharge compared to immediate cord clamping. 2. Umbilical cord milking was not statistically different from immediate or deferred cord clamping. Evidence Rating Level: 1 (Excellent) Study Rundown: Umbilical cord clamping methods in preterm births can impact postnatal health outcomes.
#VisualAbstract: Delayed cord clamping reduces mortality in infants born pre-term
1. Deferred (delayed) cord clamping significantly reduced mortality before discharge compared to immediate cord clamping. 2. Umbilical cord milking was not statistically different from immediate or deferred cord clamping. Evidence Rating Level: 1 (Excellent) Study Rundown: Umbilical cord clamping methods in preterm births can impact postnatal health outcomes.
#VisualAbstract: Perioperative pembrolizumab with chemotherapy for gastric and gastroesophageal junction adenocarcinoma improves pathological complete response rate compared with placebo - Physician's Weekly
1. The median overall survival and event-free survival were not statistically different in the pembrolizumab group as compared to the placebo group. 2. The frequency of serious adverse events (AEs) of grade 3 or worse was comparable between experimental and placebo groups. Evidence Rating Level: 1 (Excellent) Study Rundown: While the gold standard treatment for localized gastric and gastroesophageal junction (GEJ) adenocarcinomas is surgical resection, there are high recurrence rates.
#VisualAbstract: Perioperative pembrolizumab with chemotherapy for gastric and gastroesophageal junction adenocarcinoma improves pathological complete response rate compared with placebo | 2 Minute Medicine
1. The median overall survival and event-free survival were not statistically different in the pembrolizumab group as compared to the placebo group. 2. The frequency of serious adverse events (AEs) of grade 3 or worse was comparable between experimental and placebo groups. Evidence Rating Level: 1 (Excellent) Study Rundown: While the gold standard treatment for localized gastric and gastroesophageal junction (GEJ) adenocarcinomas is surgical resection, there are high recurrence rates.
#VisualAbstract: Glucagon-like peptide 1 receptor agonists (GLP-1RAs) prescribed for type 2 diabetes are associated with reduced colorectal cancer (CRC) risk compared to other antidiabetic agents - Physician's Weekly
1. In all patients, there was a 44% reduction in risk of colorectal cancer when using GLP-1RAs as compared to insulin, and a 25% reduction in risk as compared to metformin use. 2. Results for overweight patients and those with obesity showed GLP-1RAs significantly reduced risk for CRC compared with multiple antidiabetics. Evidence Rating Level: 2 (Good) Study Rundown: An important risk factor for colorectal cancer (CRC) is being overweight or obese.
#VisualAbstract: Glucagon-like peptide 1 receptor agonists (GLP-1RAs) prescribed for type 2 diabetes are associated with reduced colorectal cancer (CRC) risk compared to other antidiabetic agents | 2 Minute Medicine
1. In all patients, there was a 44% reduction in risk of colorectal cancer when using GLP-1RAs as compared to insulin, and a 25% reduction in risk as compared to metformin use. 2. Results for overweight patients and those with obesity showed GLP-1RAs significantly reduced risk for CRC compared with multiple antidiabetics. Evidence Rating Level: 2 (Good) Study Rundown: An important risk factor for colorectal cancer (CRC) is being overweight or obese.
#VisualAbstract: Weekly insulin icodec is more effective than daily basal insulin at reducing HbA1c
1. In this randomized controlled trial, insulin icodec demonstrated superior HbA1c reduction as compared to once-daily basal insulin analogs in insulin-naïve type two diabetes (T2D). 2. Insulin icodec showed improved treatment satisfaction and compliance as compared to once-daily basal insulin analogs in insulin naïve T2D.
#VisualAbstract: Weekly insulin icodec is more effective than daily basal insulin at reducing HbA1c
1. In this randomized controlled trial, insulin icodec demonstrated superior HbA1c reduction as compared to once-daily basal insulin analogs in insulin-naïve type two diabetes (T2D). 2. Insulin icodec showed improved treatment satisfaction and compliance as compared to once-daily basal insulin analogs in insulin naïve T2D.
#VisualAbstract: Low-dose amitriptyline effective and well-tolerated for management of irritable bowel syndrome
1. Low-dose amitriptyline was associated with a marked decrease in IBS-SSS score at 6 months compared to placebo. 2. There were 5 serious adverse reactions (2 in the amitriptyline group and 3 in the placebo group). Evidence Rating Level: 1 (Excellent) Study Rundown: Irritable bowel syndrome (IBS) is a functional disorder that is managed through dietary changes and lifestyle modifications.
#VisualAbstract: Low-dose amitriptyline effective and well-tolerated for management of irritable bowel syndrome
1. Low-dose amitriptyline was associated with a marked decrease in IBS-SSS score at 6 months compared to placebo. 2. There were 5 serious adverse reactions (2 in the amitriptyline group and 3 in the placebo group). Evidence Rating Level: 1 (Excellent) Study Rundown: Irritable bowel syndrome (IBS) is a functional disorder that is managed through dietary changes and lifestyle modifications.
#VisualAbstract: Tiragolumab With Atezolizumab Plus Chemotherapy in Untreated Extensive-Stage SCLC
1. Median PFS and OS between the tiragolumab and control arms were similar 2. Treatment-related AEs that were grade 3/4 occurred in 52.7% in the tiragolumab arm and 55.7% in the control arm. Evidence Rating Level: 1 (Excellent) Study Rundown: Extensive-stage small-cell lung cancer (ES-SCLC) is currently treated with atezolizumab/carboplatin/etoposide or durvalumab/chemotherapy, however, most patients have poor median survival.
#VisualAbstract: Tiragolumab With Atezolizumab Plus Chemotherapy in Untreated Extensive-Stage SCLC
1. Median PFS and OS between the tiragolumab and control arms were similar 2. Treatment-related AEs that were grade 3/4 occurred in 52.7% in the tiragolumab arm and 55.7% in the control arm. Evidence Rating Level: 1 (Excellent) Study Rundown: Extensive-stage small-cell lung cancer (ES-SCLC) is currently treated with atezolizumab/carboplatin/etoposide or durvalumab/chemotherapy, however, most patients have poor median survival.
#VisualAbstract: Berzosertib Plus Topotecan vs Topotecan Alone in Relapsed Small Cell Lung Cancer
1. The progression-free survival in berzosertib with topotecan vs topotecan alone was not statistically significant, but the overall survival was significant. 2. Grade ≥3 treatment-related adverse events were similar between both groups. Evidence Rating Level: 1 (Excellent) Study Rundown: Genomic instability plays a crucial role in the development of small cell lung cancer (SCLC), and replication stress is a major driver of this instability.
#VisualAbstract: Berzosertib Plus Topotecan vs Topotecan Alone in Relapsed Small Cell Lung Cancer
This site uses various technologies, including third-party cookies, pixels, and codes, to personalize our website functionalities, measure website usage and performance and provide targeting advertising. Information about your site visit may be stored or shared with third parties as identified in our Privacy Policy . By continuing to use this website you consent to our Privacy Policy and Terms of Use .
#VisualAbstract: Berzosertib Plus Topotecan vs Topotecan Alone in Relapsed Small Cell Lung Cancer
1. The progression-free survival in berzosertib with topotecan vs topotecan alone was not statistically significant, but the overall survival was significant. 2. Grade ≥3 treatment-related adverse events were similar between both groups. Evidence Rating Level: 1 (Excellent) Study Rundown: Genomic instability plays a crucial role in the development of small cell lung cancer (SCLC), and replication stress is a major driver of this instability.
#VisualAbstract: Esketamine augmentation therapy is superior to quetiapine for treatment-related depression
1. In this randomized controlled trial, in patients with treatment-resistant depression esketamine nasal spray as augmentation therapy was associated with higher rates of remission as compared to extended-release quetiapine. 2. Once remission was achieved, esketamine nasal spray was associated with lower risks of relapse at 32 weeks compared to extended-release quetiapine.
#VisualAbstract: Esketamine augmentation therapy is superior to quetiapine for treatment-related depression
1. In this randomized controlled trial, in patients with treatment-resistant depression esketamine nasal spray as augmentation therapy was associated with higher rates of remission as compared to extended-release quetiapine. 2. Once remission was achieved, esketamine nasal spray was associated with lower risks of relapse at 32 weeks compared to extended-release quetiapine.
#VisualAbstract: Intraventricular lavage associated with higher risk of serious adverse events
1. This single-blinded, phase 2 randomized clinical trial found that intraventricular lavage had a significantly higher rate of serious adverse events (SAE) compared with external ventricular drain (EVD) treatment. Evidence Rating Level: 1 (Excellent) IVH—characterized by bleeding within the brain’s ventricles—is typically treated with supportive care and passive drainage using an EVD.
#VisualAbstract: Intraventricular lavage associated with higher risk of serious adverse events
1. This single-blinded, phase 2 randomized clinical trial found that intraventricular lavage had a significantly higher rate of serious adverse events (SAE) compared with external ventricular drain (EVD) treatment. Evidence Rating Level: 1 (Excellent) IVH—characterized by bleeding within the brain’s ventricles—is typically treated with supportive care and passive drainage using an EVD.
#VisualAbstract: Early versus delayed antihypertensive treatment in patients with acute ischaemic stroke
1. In this randomized controlled trial, early compared to late blood pressure management following an acute ischemic stroke did not impact the risk of death or functional dependency at 90 days. Evidence rating level: 1 (Excellent) Researchers aimed to determine whether early treatment of hypertension after an ischemic stroke impacts the risk of death or functional dependency (modified Rankin scale score ≥3).
#VisualAbstract: Early versus delayed antihypertensive treatment in patients with acute ischaemic stroke
1. In this randomized controlled trial, early compared to late blood pressure management following an acute ischemic stroke did not impact the risk of death or functional dependency at 90 days. Evidence rating level: 1 (Excellent) Researchers aimed to determine whether early treatment of hypertension after an ischemic stroke impacts the risk of death or functional dependency (modified Rankin scale score ≥3).
#VisualAbstract:Complete revascularization reduces mortality in older adults with myocardial infarction
1. In this randomized controlled trial, complete revascularization reduced the risk of myocardial infarction, stroke, or ischemia-driven revascularization at one year in patients with myocardial infarction compared to culprit lesion revascularization. 2. There was no difference in safety outcomes, including acute kidney injury, stroke, or bleeding, between groups.
Show More
loading
Actions
Is this you?
As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work.Get in touch with Alisha M.
Contact Alisha M., search articles and posts on X, monitor coverage, and track replies from one place.
Learn more about Muck Rack